TOLREMO therapeutics

TOLREMO therapeutics

TOLREMO therapeutics

TOLREMO therapeutics AG is an ETH spinoff focused on the discovery and development of small molecules to prevent resistance in cancer therapy.
Raised
$9.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$9,300,000
Venture capital (Series A) - 2018
BioMedPartners
Team Size
1–10
Employees
$9,300,000 Venture capital (Series A)
FinSMEs

Tolremo Raises CHF9.0M in Series A Funding

Funding Health